CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies (scientific article)

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

Q24645530

A Blueprint for HIV Vaccine Discovery

Q26829865

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

Q27316899

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Q27641517

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Q27644478

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

Q27648643

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

Q27658449

Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged

Q27664038

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Q27675032

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Q27675879

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

Q27677104

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

Q27677117

Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization

Q27678112

Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops

Q27678226

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

Q27678306

Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors

Q27678493

Core structure of gp41 from the HIV envelope glycoprotein

Q27736064

Atomic structure of the ectodomain from HIV-1 gp41

Q27738021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

Q27759364

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

Q28118386

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

Q28259668

The antigenic structure of the HIV gp120 envelope glycoprotein

Q28274698

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

Q28282895

Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein

Q28534454

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

Q28646817

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

Q28646859

CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization

Q28646881

A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding

Q28646883

Antibody neutralization and escape by HIV-1

Q29547345

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Q29547347

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Q29547531

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Q29614531

Broad neutralization coverage of HIV by multiple highly potent antibodies

Q29615361

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

Q29616094

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Q29617377

Structure of a V3-containing HIV-1 gp120 core

Q29619014

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

Q29619017

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Q29619510

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state

Q33426352

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

Q33444658

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

Q33504604

Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing

Q33680395

Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.

Q33951963

Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds

Q33964006

Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum

Q34280115

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Q34303849

Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening

Q34626673

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

Q34630446

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes

Q35034268

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

Q35076717

Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Q35857331

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity

Q35857631

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Q36083337

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

Q36403587

Optimization of CD4/gp120 Inhibitors by Thermodynamic‐Guided Alanine‐Scanning Mutagenesis

Q36481088

Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

Q36649958

Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions

Q36650881

Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.

Q36824891

Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design

Q36978861

Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.

Q37002237

N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies

Q37010852

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

Q37033294

Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer

Q37049334

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma

Q37051645

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies.

Q37063013

Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation

Q37157165

Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.

Q37419199

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Q37519312

Toward an antibody-based HIV-1 vaccine

Q37613695

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Q39457063

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Q39605077

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity

Q39934862

Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains

Q40621073

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies

Q40682865

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Q41151327

Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients

Q41936910

Mining the mechanisms of an HIV vaccine

Q43950239

Fc receptor but not complement binding is important in antibody protection against HIV.

Q46545827

A role for carbohydrates in immune evasion in AIDS

Q47982875

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Q48378749

Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches

Q51791621

Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Q53851964

Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line

Q55245697

Progress in HIV-1 vaccine development

Q56600657

Moving ahead an HIV vaccine: Use both arms to beat HIV

Q85075341

P433

issue

P304

page(s)

6542-6555